Drug firm Glenmark today said it has received final approval from the US health regulator for its generic Mupirocin ointment, used for the treatment of bacterial skin infections.
Glenmark Generics, the US subsidiary of Glenmark Generics, has been granted a final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (USFDA) for Mupirocin Ointment USP 2%, the company said in a statement.
"Based on IMS health data for the 12-month period ending March 2011, Mupirocin ointment garnered annual sales of $55 million and achieved a 9% increase in growth compared to the same period last year," Glenmark said.
The ointment is used for treatment of impetigo, a bacterial skin infection, and is available in a 22-gram tube.
The company's current portfolio consists of 68 products authorised for distribution in the American market. It has 39 ANDAs pending approval, Glenmark said.
Shares of Glenmark Pharmaceuticals were being quoted at Rs 313.40 apiece in late morning trade on the Bombay Stock Exchange today, up 1.56% from their previous close.
